Researchers of a recent study evaluated 305 patients with early-stage ERBB2/HER2-positive breast cancer and 6 B-cell–related signatures, to determine if a particular immune-related biomarker was better at predicting event-free survival in these patients. The biomarkers observed were tumor-infiltrating lymphocytes and immune-related gene expression signatures. Results suggested that the combined use of both of these signatures, along with multiple B-cell related signatures, were more strongly connected to identifying and predicting breast cancer with the diagnostic use of RNA sequencing than one method alone.


Fernandez-Martinez A, Pascual T, Singh B, et al. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials. JAMA Oncol. 2023;10.1001/jamaoncol.2022.6288. doi:10.1001/jamaoncol.2022.6288